Cancer Gene Therapy Market Projected to Garner Significant Revenues by 2023
A Comprehensive research study conducted by KD Market Insights on " Cancer Gene Therapy Market - by Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer) - Global Opportunity Analysis and Industry Forecast, 2017-2023" report offers extensive and highly detailed historical, current and future market trends in the global and regional/market. The Cancer Gene Therapy Market report includes market size, growth drivers, barriers, opportunities, trends and other information which helps to find new opportunities in this market for the growth of the business through new technologies and developments.
Gene therapy is an experimental technique that encompasses the replacement of mutated genes with healthy genes. During the treatment of cancer, the genes are replaced to fight against carcinogenic tumor cells. Gene therapy is considered to be an effective treatment for chronic diseases as they cause minimum side effects with maximum efficacy. The global cancer gene therapy market was valued at $289 million in 2016, and is estimated to reach $2,082 million by 2023, registering a CAGR of 32.4% from 2017 to 2023.
Request for Sample @ https://www.kdmarketinsights.com/sample/4340
The rise in prevalence of cancer, benefits of cancer gene therapy over conventional cancer therapies, and the advancement in this field are the major factors that drive the market growth. In addition, increase in government support, ethical acceptance of gene therapy for cancer treatment, and rise in biotechnological funding encourage the R&D activities for cancer gene therapy and thus fuel the growth of the cancer gene therapy market. However, high cost associated with the treatment and unwanted immune responses are expected to restrain the market growth.
The global cancer gene therapy market is segmented based on therapy, end user, and geography. Based on therapy, it is categorized into gene induced immunotherapy (delivery of cytokines gene and delivery of tumor antigen gene), oncolytic virotherapy (adenovirus, lentivirus, retro virus, adeno associated virus, herpes simplex virus, alpha virus, vaccinia virus, simian virus, and others), and gene transfer (naked plasmid vector, electroporation, sonoportion, magnetofection, and gene gun). Based on geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
- The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
- In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
- The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.
KEY PLAYERS PROFILED
- Adaptimmune
- GlaxoSmithKline
- Bluebird bio, Inc.
- Merck
- Celgene
- Shanghai Sunway Biotech
- BioCancell
- Shenzhen SiBiono GeneTech
- SynerGene Therapeutics
- OncoGenex Pharmaceuticals
KEY MARKET SEGMENTS
By Therapy
- Gene Induced Immunotherapy
- - - Delivery of Cytokines Gene
- - - Delivery of Tumor Antigen Gene
- Oncolytic Virotherapy
- - - Adenovirus
- - - Lentivirus
- - - Retro Virus
- - - Adeno Associated Virus
- - - Herpes Simplex Virus
- - - Alpha Virus
- - - Vaccinia Virus
- - - Simian Virus
- - - Others
- Gene Transfer
- - - Naked/Plasmid Vectors
- - - Electroporation
- - - Sonoportion
- - - Magnetofection
- - - Gene Gun
By End User
- Hospitals
- Diagnostics Centers
- Research Institutes
By Region
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- Rest of Asia-Pacific
LAMEA
- Brazil
- Republic of South Africa
- Saudi Arabia
- Rest of LAMEA
Browse Full Report with TOC @ https://www.kdmarketinsights.com/product/cancer-gene-therapy-market-amr
Table of Contents:
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. REGULATION AND REIMBURSEMENT SCENARIO
3.4. PORTERS FIVE FORCES ANALYSIS
3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities
CHAPTER 4 CANCER GENE THERAPY MARKET, BY THERAPY
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. ONCOLYTIC VIROTHERAPY
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Adenovirus
4.2.5. Lentivirus
4.2.6. Retro virus
4.2.7. Adeno associated virus
4.2.8. Herpes simplex virus
4.2.9. Alpha Virus
4.2.10. Vaccinia Virus
4.2.11. Simian Virus
4.2.12. Others
4.3. GENE TRANSFER
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Naked plasmid vector
4.3.5. Electroporation
4.3.6. Sonoportion
4.3.7. Magnetofection
4.3.8. Gene Gun
4.4. GENE-INDUCED IMMUNOTHERAPY
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Delivery of cytokines gene
4.4.5. Delivery of tumor antigen gene
CHAPTER 5 CANCER GENE THERAPY MARKET, BY GEOGRAPHY
5.1. OVERVIEW
5.2. NORTH AMERICA
5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast
5.2.3.1. U.S. market size and forecast
5.2.3.2. Canada market size and forecast
5.2.3.3. Mexico market size and forecast
5.2.4. North America Cancer gene therapy Market by Therapy
5.3. EUROPE
5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast
5.3.3.1. Germany market size and forecast
5.3.3.2. France market size and forecast
5.3.3.3. UK market size and forecast
5.3.3.4. Italy market size and forecast
5.3.3.5. Spain market size and forecast
5.3.3.6. Rest of Europe market size and forecast
5.3.4. Europe Cancer gene therapy Market by Therapy
5.4. ASIA-PACIFIC
5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast
5.4.3.1. Japan market size and forecast
5.4.3.2. China market size and forecast
5.4.3.3. Australia market size and forecast
5.4.3.4. India market size and forecast
5.4.3.5. South Korea market size and forecast
5.4.3.6. Taiwan market size and forecast
5.4.3.7. Rest of Asia-Pacific market size and forecast
5.4.4. Asia-Pacific Cancer gene therapy Market by Therapy
5.5. LAMEA
5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast
5.5.3.1. Brazil market size and forecast
5.5.3.2. Turkey market size and forecast
5.5.3.3. Saudi Arabia market size and forecast
5.5.3.4. South Africa market size and forecast
5.5.3.5. Rest of LAMEA market size and forecast
5.5.4. LAMEA Cancer gene therapy Market by Therapy
CHAPTER 6 COMPANY PROFILES
6.1. ADAPTIMMUNE
6.1.1. Operating business segments
6.1.2. Business performance
6.1.3. Key strategic moves and developments
6.2. GLAXOSMITHKLINE
6.2.1. Operating business segments
6.2.2. Business performance
6.2.3. Key strategic moves and developments
6.3. BLUEBIRD BIO, INC.
6.3.1. Operating business segments
6.3.2. Business performance
6.3.3. Key strategic moves and developments
6.4. MERCK
6.4.1. Operating business segments
6.4.2. Business performance
6.4.3. Key strategic moves and developments
6.5. CELGENE
6.5.1. Operating business segments
6.5.2. Business performance
6.5.3. Key strategic moves and developments
6.6. SHANGHAI SUNWAY BIOTECH
6.6.1. Operating business segments
6.6.2. Business performance
6.6.3. Key strategic moves and developments
6.7. BIOCANCELL
6.7.1. Operating business segments
6.7.2. Business performance
6.7.3. Key strategic moves and developments
6.8. SHENZHEN SIBIONO GENETECH
6.8.1. Operating business segments
6.8.2. Business performance
6.8.3. Key strategic moves and developments
6.9. SYNERGENE THERAPEUTICS
6.9.1. Operating business segments
6.9.2. Business performance
6.9.3. Key strategic moves and developments
6.10. ONCOGENEX PHARMACEUTICALS
Continue….
Check for Discount @ https://www.kdmarketinsights.com/discount/4340
About Us:
KD Market Insights is one of the leading providers of market intelligence products and services. We offer reports on over 10+ industries and update our collection daily which helps our clients to access database of expert market insights on global industries, companies, products, and trends. Our in-house research experts have a wealth of knowledge in their respective domains. With KD Market Research, you always have the choice of getting customized report free of cost (up to 10%). Our support team will help you customize the report and scope as per your business needs. This ensures that you are making the right purchase decision.
Our clients list includes various Fortune 500 companies and leading advisory firms.
Contact Us:
KD Market Insights
90 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: info@kdmarketinsights.com
Website: www.kdmarketinsights.com
Read More News: https://consumersgoods745245330.wordpress.com/
https://ictindustry9.blogspot.com/
Gene therapy is an experimental technique that encompasses the replacement of mutated genes with healthy genes. During the treatment of cancer, the genes are replaced to fight against carcinogenic tumor cells. Gene therapy is considered to be an effective treatment for chronic diseases as they cause minimum side effects with maximum efficacy. The global cancer gene therapy market was valued at $289 million in 2016, and is estimated to reach $2,082 million by 2023, registering a CAGR of 32.4% from 2017 to 2023.
Request for Sample @ https://www.kdmarketinsights.com/sample/4340
The rise in prevalence of cancer, benefits of cancer gene therapy over conventional cancer therapies, and the advancement in this field are the major factors that drive the market growth. In addition, increase in government support, ethical acceptance of gene therapy for cancer treatment, and rise in biotechnological funding encourage the R&D activities for cancer gene therapy and thus fuel the growth of the cancer gene therapy market. However, high cost associated with the treatment and unwanted immune responses are expected to restrain the market growth.
The global cancer gene therapy market is segmented based on therapy, end user, and geography. Based on therapy, it is categorized into gene induced immunotherapy (delivery of cytokines gene and delivery of tumor antigen gene), oncolytic virotherapy (adenovirus, lentivirus, retro virus, adeno associated virus, herpes simplex virus, alpha virus, vaccinia virus, simian virus, and others), and gene transfer (naked plasmid vector, electroporation, sonoportion, magnetofection, and gene gun). Based on geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
- The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
- In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
- The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.
KEY PLAYERS PROFILED
- Adaptimmune
- GlaxoSmithKline
- Bluebird bio, Inc.
- Merck
- Celgene
- Shanghai Sunway Biotech
- BioCancell
- Shenzhen SiBiono GeneTech
- SynerGene Therapeutics
- OncoGenex Pharmaceuticals
KEY MARKET SEGMENTS
By Therapy
- Gene Induced Immunotherapy
- - - Delivery of Cytokines Gene
- - - Delivery of Tumor Antigen Gene
- Oncolytic Virotherapy
- - - Adenovirus
- - - Lentivirus
- - - Retro Virus
- - - Adeno Associated Virus
- - - Herpes Simplex Virus
- - - Alpha Virus
- - - Vaccinia Virus
- - - Simian Virus
- - - Others
- Gene Transfer
- - - Naked/Plasmid Vectors
- - - Electroporation
- - - Sonoportion
- - - Magnetofection
- - - Gene Gun
By End User
- Hospitals
- Diagnostics Centers
- Research Institutes
By Region
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- Rest of Asia-Pacific
LAMEA
- Brazil
- Republic of South Africa
- Saudi Arabia
- Rest of LAMEA
Browse Full Report with TOC @ https://www.kdmarketinsights.com/product/cancer-gene-therapy-market-amr
Table of Contents:
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. REGULATION AND REIMBURSEMENT SCENARIO
3.4. PORTERS FIVE FORCES ANALYSIS
3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities
CHAPTER 4 CANCER GENE THERAPY MARKET, BY THERAPY
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. ONCOLYTIC VIROTHERAPY
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Adenovirus
4.2.5. Lentivirus
4.2.6. Retro virus
4.2.7. Adeno associated virus
4.2.8. Herpes simplex virus
4.2.9. Alpha Virus
4.2.10. Vaccinia Virus
4.2.11. Simian Virus
4.2.12. Others
4.3. GENE TRANSFER
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Naked plasmid vector
4.3.5. Electroporation
4.3.6. Sonoportion
4.3.7. Magnetofection
4.3.8. Gene Gun
4.4. GENE-INDUCED IMMUNOTHERAPY
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Delivery of cytokines gene
4.4.5. Delivery of tumor antigen gene
CHAPTER 5 CANCER GENE THERAPY MARKET, BY GEOGRAPHY
5.1. OVERVIEW
5.2. NORTH AMERICA
5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast
5.2.3.1. U.S. market size and forecast
5.2.3.2. Canada market size and forecast
5.2.3.3. Mexico market size and forecast
5.2.4. North America Cancer gene therapy Market by Therapy
5.3. EUROPE
5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast
5.3.3.1. Germany market size and forecast
5.3.3.2. France market size and forecast
5.3.3.3. UK market size and forecast
5.3.3.4. Italy market size and forecast
5.3.3.5. Spain market size and forecast
5.3.3.6. Rest of Europe market size and forecast
5.3.4. Europe Cancer gene therapy Market by Therapy
5.4. ASIA-PACIFIC
5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast
5.4.3.1. Japan market size and forecast
5.4.3.2. China market size and forecast
5.4.3.3. Australia market size and forecast
5.4.3.4. India market size and forecast
5.4.3.5. South Korea market size and forecast
5.4.3.6. Taiwan market size and forecast
5.4.3.7. Rest of Asia-Pacific market size and forecast
5.4.4. Asia-Pacific Cancer gene therapy Market by Therapy
5.5. LAMEA
5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast
5.5.3.1. Brazil market size and forecast
5.5.3.2. Turkey market size and forecast
5.5.3.3. Saudi Arabia market size and forecast
5.5.3.4. South Africa market size and forecast
5.5.3.5. Rest of LAMEA market size and forecast
5.5.4. LAMEA Cancer gene therapy Market by Therapy
CHAPTER 6 COMPANY PROFILES
6.1. ADAPTIMMUNE
6.1.1. Operating business segments
6.1.2. Business performance
6.1.3. Key strategic moves and developments
6.2. GLAXOSMITHKLINE
6.2.1. Operating business segments
6.2.2. Business performance
6.2.3. Key strategic moves and developments
6.3. BLUEBIRD BIO, INC.
6.3.1. Operating business segments
6.3.2. Business performance
6.3.3. Key strategic moves and developments
6.4. MERCK
6.4.1. Operating business segments
6.4.2. Business performance
6.4.3. Key strategic moves and developments
6.5. CELGENE
6.5.1. Operating business segments
6.5.2. Business performance
6.5.3. Key strategic moves and developments
6.6. SHANGHAI SUNWAY BIOTECH
6.6.1. Operating business segments
6.6.2. Business performance
6.6.3. Key strategic moves and developments
6.7. BIOCANCELL
6.7.1. Operating business segments
6.7.2. Business performance
6.7.3. Key strategic moves and developments
6.8. SHENZHEN SIBIONO GENETECH
6.8.1. Operating business segments
6.8.2. Business performance
6.8.3. Key strategic moves and developments
6.9. SYNERGENE THERAPEUTICS
6.9.1. Operating business segments
6.9.2. Business performance
6.9.3. Key strategic moves and developments
6.10. ONCOGENEX PHARMACEUTICALS
Continue….
Check for Discount @ https://www.kdmarketinsights.com/discount/4340
About Us:
KD Market Insights is one of the leading providers of market intelligence products and services. We offer reports on over 10+ industries and update our collection daily which helps our clients to access database of expert market insights on global industries, companies, products, and trends. Our in-house research experts have a wealth of knowledge in their respective domains. With KD Market Research, you always have the choice of getting customized report free of cost (up to 10%). Our support team will help you customize the report and scope as per your business needs. This ensures that you are making the right purchase decision.
Our clients list includes various Fortune 500 companies and leading advisory firms.
Contact Us:
KD Market Insights
90 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: info@kdmarketinsights.com
Website: www.kdmarketinsights.com
Read More News: https://consumersgoods745245330.wordpress.com/
https://ictindustry9.blogspot.com/
Comments
Post a Comment